KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Free Cash Flow: 2009-2024

Historic Free Cash Flow for Emergent BioSolutions (EBS) over the last 16 years, with Dec 2024 value amounting to $35.8 million.

  • Emergent BioSolutions' Free Cash Flow fell 103.85% to -$5.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.4 million, marking a year-over-year decrease of 98.99%. This contributed to the annual value of $35.8 million for FY2024, which is 113.88% up from last year.
  • Per Emergent BioSolutions' latest filing, its Free Cash Flow stood at $35.8 million for FY2024, which was up 113.88% from -$257.9 million recorded in FY2023.
  • In the past 5 years, Emergent BioSolutions' Free Cash Flow registered a high of $395.0 million during FY2020, and its lowest value of -$277.8 million during FY2022.
  • Its 3-year average for Free Cash Flow is -$166.6 million, with a median of -$257.9 million in 2023.
  • In the last 5 years, Emergent BioSolutions' Free Cash Flow surged by 290.70% in 2020 and then crashed by 389.07% in 2022.
  • Yearly analysis of 5 years shows Emergent BioSolutions' Free Cash Flow stood at $395.0 million in 2020, then crashed by 75.67% to $96.1 million in 2021, then plummeted by 389.07% to -$277.8 million in 2022, then rose by 7.16% to -$257.9 million in 2023, then surged by 113.88% to $35.8 million in 2024.